Relationship of The Lung Microbiome With PD-L1 Expression And Immunotherapy Response in Lung Cancer

doi:10.21203/rs.3.rs-960381/v1

Background: Lung cancer is the primary cause of cancer-related deaths worldwide. The human lung serves as a niche to a unique and dynamic bacterial community that is related to the development of multiple diseases. Here, we investigated the differences in the lung microbiomes of patients with lung cancer.

Methods: 16S rRNA sequencing was performed to evaluate the respiratory tract microbiome present in the bronchoalveolar lavage fluid. Patients were stratified based on programmed death-ligand 1 (PD-L1) expression levels and immunotherapy responses.

Results: In total, 84 patients were prospectively analyzed, of which 59 showed low (<10%), and 25 showed high (>10%) PD-L1 expression levels. The alpha and beta diversities did not significantly differ between the two groups. Veillonella dispar was dominant in the high-PD-L1 group; the population of Neisseria was significantly higher in the low-PD-L1 group than in the high-PD-L1 group. In the immunotherapy responder group, V. dispar was dominant, while Haemophilus influenzae and Neisseria perflava were dominant in the non-responder group.

Conclusion: The abundances of Neisseria and V. dispar differed significantly in relation to PD-L1 expression levels and immunotherapy responses. Thus, these two genera may be considered targets for lung cancer immunotherapy.

Pulmonology

human microbiome

taxonomy

lung cancer

PD-L1 expression levels

Lung cancer is the main cause of cancer-related deaths worldwide. In 2020, 228,820 deaths reported in the United States were attributed to lung cancer, which was approximately a quarter of all reported cancer-related deaths.[1, 2] Targeted therapy for biomarkers, such as epidermal growth factor receptor, anaplastic lymphoma kinase, receptor tyrosine kinase ROS1, receptor tyrosine kinase RET, serine/threonine-protein kinase B-Raf, and immunotherapy using anticancer drugs such as checkpoint inhibitors result in relatively high progression-free survival and total survival, compared to traditional anticancer drug treatments (for example, platinum-based chemotherapy). However, the prognosis of lung cancer patients remains poor.[3]

The human lungs serve as a niche for a unique and dynamic bacterial community, characterized by the bi-directional movement of non-sterile air and mucus in the airways.[4] During respiratory diseases, significant differences in community composition between healthy and diseased lungs were observed.[5] Recent studies using next-generation sequencing have revealed that the lung microbiome in patients with lung cancer differs from that in healthy individuals.[6–8] Several studies have suggested a link between the lung microbiome and chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and respiratory infection.[5] For example, previous COPD studies on the microbiome showed that its severity increases as microbiome diversity decreases and that the microbiome affects the acute exacerbation of COPD.[9] Microbiota have been shown to modulate the efficacy and toxicity of cancer therapy, including chemotherapy and immunotherapy.[10] Preclinical data have suggested that modulation of the microbiota may present a novel strategy for improving the efficacy of immunotherapies for cancer, particularly, checkpoint blockade approaches targeting the cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) pathways.[11, 12]

Understanding the mechanisms through which microorganisms present in the respiratory tract may influence lung carcinoma development and treatment efficacy may be the key to predict the risk of cancer development and improve treatment efficacy and safety.[13]

Microbial changes are thought to be associated with the accumulation of a PD-L1 dependent T regulatory cell population that promotes tolerance to environmental allergens.[14] Therefore, we hypothesized that the composition of the microbiome might differ based on PD-L1 expression levels. This study aimed to investigate the microbial differences in patients with lung cancer according to PD-L1 expression levels. In addition, we investigated whether there was a difference in the microbiome between responders and non-responders to immunotherapy.

Patient Recruitment and Sample Collection

From June 1, 2018, to June 31, 2020, we prospectively recruited 84 patients who were pathologically diagnosed with non-small cell lung cancer (NSCLC) in two tertiary hospitals, Severance Hospital and Bundang Seoul Hospital, South Korea. Bronchoalveolar lavage (BAL) fluid samples were collected by a bronchoscopy specialist using a sterile bronchoscope.

Definition of Chemotherapy Response

The response to cancer treatment was divided into four categories according to the RECIST guideline.[15] Accordingly, patients who showed progressive disease (PD) after 3 months of cancer treatment were classified as non-responders, whereas patients who showed stable disease (SD), partial response (PR), and complete resolution were considered responders.

Statistical Analysis

Categorical variables are reported as numbers (percentages). Continuous variables with normal distribution are reported as means ± standard deviations, whereas variables with abnormal distribution are reported as medians with interquartile ranges (IQR, 25th to 75th percentiles). Categorical variables were compared using the chi-square test, and continuous variables were compared using either an independent t-test or Mann–Whitney U test according to the normality of distribution. A value of p < 0.05 indicated significance. All statistical analyses were performed using IBM SPSS Statistics version 25.0 (IBM, Armonk, NY, USA).

Ethics Approval and Patient Consent

The research protocol was approved by the Institutional Review Board of Severance Hospital, South Korea (IRB No. 4-0018-0313), and Seoul National University Bundang Hospital, South Korea (IRB No. B-1610/365-302). The study design was approved by the appropriate ethics review boards, and informed patient consent was obtained.

Characteristics of the Subjects

From June 1, 2018, to June 31, 2020, a total of 84 patients, who were pathologically diagnosed with non-small cell lung cancer (NSCLC) in two tertiary hospitals, Severance Hospital and Bundang Seoul Hospital, South Korea, were recruited in this prospective study.

The baseline characteristics of the two groups are shown in Table 1. The patients were stratified into two groups: 59 patients belonged to the low PD-L1 (<10%) group, and 25 belonged to the high PD-L1 (>10%) group. The mean age was 66.7 ± 11.2 years. Male was the dominant sex in both groups (61.0% vs. 64.0%); most of the patients had adenocarcinoma (76.3% in the low PD-L1 group vs. 76.0% in the high PD-L1 group), and the rest were diagnosed with squamous cell carcinoma. In the low PD-L1 group, the proportion of early-stage lung cancer was higher; contrastingly, patients with advanced-stage lung cancer were more abundant in the high PD-L1 group.

Table 1

Demographics and clinical characteristics of patients
Characteristics	PD-L1 < 10%	PD-L1≥10%	Total	P-value
No.	59 (70.2)	25 (29.8)	84 (100.0)
Age	68.1 ± 10.7	63.1 ± 12.9	66.7 ± 11.2	0.080
Gender				0.797
Male, n (%)	36 (61.0)	16 (64.0)	52 (61.9)
Female, n (%)	23 (39.0)	9 (36.0)	32 (38.1)
Smoking history				0.574
Current or former, n (%)	32 (54.2)	16 (64.0)	48 (57.1)
Never, n (%)	27 (45.8)	9 (36.0)	36 (42.9)
Smoking amount (pack-years)	32.1 ± 15.6	30.2 ± 15.5	31.5 ± 15.4	0.687
Immunotherapy responder	6 (10.2)	2 (8.0)
Immunotherapy non-responder	2 (3.4)	1 (4.0)
Neutrophil-Lymphocyte ratio	2.93 (1.94, 6.13)	3.14 (1.76, 5.09)	3.05 (1.91, 5.85)	0.889
Stage, n (%)				0.084
I/II/III/IV	24/6/14/15	3/4/9/9	27/10/23/24
Pathologic diagnosis				0.979
Adenocarcinoma, n (%)	45 (76.3)	19 (76.0)	64 (76.2)
Squamous cell carcinoma, n (%)	14 (23.7)	6 (24.0)	20 (23.8)
PD-L1, programmed death-ligand 1.

Of the 84 patients, the microbiome from 11 patients who underwent immunotherapy was analyzed (Table 2). Patients who showed SD, CR or PR after 3 months of immunotherapy were assigned to the responder group (eight patients), and patients showing PD were assigned to the non-responder group (three patients). The median age was 63.0 years.

Table 2

Demographics and clinical characteristics between the immunotherapy responder and non-responder groups
Characteristics	Responder	Non-responder	Total	P-value
No.	8 (72.7)	3 (27.3)	11 (100.0)
Age	63.0 (54.5, 73.8)	62.0 (50.0, 62.0)	63.0 (54.0, 74.0)	0.840
Gender				0.491
Male, n (%)	7 (87.5)	2 (66.7)	9 (81.8)
Female, n (%)	1 (12.5)	1 (33.3)	2 (18.2)
Smoking history				0.179
Current or former, n (%)	7 (87.5)	2 (66.7)	9 (81.8)
Never, n (%)	1 (12.5)	1 (33.3)	2 (18.2)
Pack-years	35.0 (30.0, 40.0)	41.5 (33.0, 41.5)	35.0 (30.0, 45.0)	0.526
Neutrophil-lymphocyte ratio	2.63 (2.13, 4.36)	1.98 (1.86, 1.98)	2.27 (1.98, 3.76)	0.133
PD-L1≥10%	2 (25.0)	1 (33.3)
PD-L1<10%	6 (75.0)	2 (66.7)
Stage				0.361
I/II/III/IV	0/1/4/3	0/0/1/2	0/1/5/5
Pathologic diagnosis				0.661
Adenocarcinoma, n (%)	6 (75.0)	2 (66.7)	8 (72.7)
Squamous cell carcinoma, n (%)	2 (25.0)	1 (33.3)	3 (27.3)

Characterization of the Lung Microbiome Based on PD-L1 Expression Levels

Figure 1a and b shows the differences in the lung microbiome according to PD-L1 expression levels. In the high-PD-L1 group, the dominant phyla were Bacteroidetes (39.4%), Firmicutes (30.5%), Proteobacteria (19.1%), Fusobacteria (6.4%), and Acinetobacter (3.2%). In the low-PD-L1 group, the phyla Bacteroidetes (39.4%), Proteobacteria (28.2%), Firmicutes (23.2%), Fusobacteria (5.1%), and Acinetobacter (2.8%) were dominant.

Proteobacteria and Firmicutes abundances differed between the low- and high-PD-L1 groups (Wilcoxon test, p = 0.051, Figure 1c; p = 0.045, Figure 1d). The Simpson index was evaluated to estimate the α diversity in the lung microbiome. The species richness differed between the two groups based on the Shannon index (p = 0.866, Figure 1e) and Simpson index (p = 0.247, Figure 1f), while the variability was not statistically significant. The Bray–Curtis distance was calculated to estimate the β diversity in the lung taxonomy community structure in patients with NSCLC; however, there was no significant difference between the groups according to PD-L1 expression level (Supplemental Figure 1).

LEFse analysis to further evaluate the differences in these dominant genera between patients with NSCLC in the low- and high-PD-L1 groups showed that the genus Neisseria, which belongs to the phylum Proteobacteria, was significantly more abundant in the low-PD-L1 group (Wilcoxon test, p = 0.037), and was also the genus with the greatest influence on the distinction between the two groups, with an LDA (linear discriminant analysis) score of 4.56 (Figure 2). Veillonella dispar, belonging to the Firmicutes phylum, was dominant in the high-PD-L1 group (Wilcoxon test, p = 0.028, Figure 2).

Taxonomy Composition in Patients with Lung Cancer in the Responder and Non-responder Groups

In the responder group, the dominant phyla were Bacteroidetes (46.8%), Firmicutes (26.2%), Proteobacteria (19.0%), Fusobacteria (3.5%), and Acinetobacter (3.4%). The dominant genera were Prevotella (36.4%), Veillonella (12.6%), Haemophilus (11.4%), Alloprevotella (7.3%), Neisseria (5.1%), Streptococcus (4.9%), and Porphyromonas (2.0%). Dominant phyla in the non-responder group included Bacteroidetes (36.8%), Proteobacteria (34.6%), Firmicutes (20.4%), and Fusobacteria (4.4%). Dominant genera included Prevotella (29.2%), Haemophilus (26.4%), Neisseria (6.7%), Alloprevotella (6.4%), Veillonella (6.2%), and Megasphaera (4.4%). The dominant phyla and genera in the immunotherapy responder and non-responder groups are shown in Figure 3a and b.

Proteobacteria and Bacteroidetes populations were higher (Wilcoxon test, p = 0.414, Figure 3c; p = 0.153, Figure 3d), whereas that of the phylum Firmicutes was lower (Wilcoxon test, p = 0.414, Figure 3e) in the non-responder group than in the responder group.

The Shannon and Simpson indices were evaluated to estimate the α diversity in the lung microbiome. The community in each microbiome was different; however, the difference was not significant (p = 0.307 for Shannon, Figure 2f; p = 0.540 for Simpson index, Figure 3g).

We analyzed the differential taxonomy in BAL fluid samples between the patients with NSCLC in different response groups. LEFse analysis was performed to further evaluate the differences in the genera present in samples (Figure 4). The population of Haemophilus, which belongs to the Proteobacteria phylum, was significantly higher in the non-responder group (Wilcoxon test, p = 0.041), whereas Veillonella was dominant in the responder group (Wilcoxon test, p = 0.041). It was also the genus that had the greatest effect on the difference between the responder and non-responder groups, with an LDA score of 5.1 for Haemophilus influenzae and 4.4 for Neisseria perflava in the non-responder group, and an LDA score of 4.1 for V. dispar (p = 0.041) in the responder group. The difference in the genera might have been related to the response to immunotherapy in patients with NSCLC.

In this study, we analyzed the bronchial microbiome in patients with NSCLC by performing 16S rRNA gene sequencing to analyze the relationship among microbiota composition, response to immunotherapy, and PD-L1 expression level. The ratio of Firmicutes to Bacteroidetes and the proportion of Veillonella were higher in the high-PD-L1 and immunotherapy responder groups than in the low-PD-L1 and non-responder groups.

In healthy individuals, the microbiota contributes to barrier function, communicates with the exterior, plays a role in immune homeostasis, and enhances anticancer immune surveillance via tumor antigenicity.[16] Additionally, the microbiota can trigger systemic innate immune responses via pattern recognition receptors, which further activate host responses against tumor cells.[17]

Recent studies have shown that the gut microbiota affects the responses to immune checkpoint blockade therapy in patients with cancer.[18–20] The transplantation of fecal microbiota has been reported to augment and restore human immune responses, resulting in increased sensitivity to immunotherapy.[21] Recent studies have reported that organ-specific microbiomes, such as the lung microbiome, play an important role in lung cancer development.[22]

Overall, our study did not show significant differences in the abundances of phyla in culture-independent DNA-based molecular assays; however, certain estimates of species richness showed significant differences in the PD-L1 expression groups.

There was a significant difference in culture-based genus types according to the differences in PD-L1 expression levels and immunotherapy responses. DNA sequencing analysis showed that the abundances of the genera Neisseria, Veillonella, and Haemophilus differed significantly between the two groups.

Regarding the LDA score indicating the effect size, the genus with the highest score in the low-PD-L1 group was Neisseria of the Proteobacteria phylum. In the non-responder group, the LDA score of N. perflava was significantly increased. This result suggested that Neisseria may be associated with PD-L1 expression levels and immunotherapy responses. It was previously reported that Proteobacteria abundance markedly increased in an anti-PD-L1 immunotherapy non-responder group of hepatocellular carcinoma.[23] However, the causal relationship of these correlations is not understood, and further research is needed.

V. dispar was dominant in the high-PD-L1 and immunotherapy responder groups. At present, studies show that the genus Veillonella is associated with the development of asthma[24, 25] and acute exacerbation of idiopathic pulmonary fibrosis.[26] Furthermore, Yan et al.[27] reported that Veillonella is abundant in patients with squamous cell carcinoma and adenocarcinoma of lung cancer, compared to healthy patients. They found that Veillonella may be used as a diagnostic marker to evaluate the development of both squamous cell carcinoma and adenocarcinoma.[28] Based on the findings of these studies, Veillonella present in samples collected from the airways may be associated with the development of multiple lung diseases. Our study further revealed that the Veillonella population was additionally associated with the responses to immunotherapy.

Tumor immunotherapy is performed not only to kill cancer cells but also to provide a long-term protective immunity mediated by memory CD8⁺ T cells.[29, 30] During cancer progression, the dysfunction in CD8⁺ T cell engagement and exhaustion owing to the tumor microenvironment results in an impairment in their function.[31] Identification of bacteria that directly or indirectly induce antitumor activities is crucial to developing microbiome-based combinatory treatments that can improve the overall response rate of anti-PD-1/PD-L1 treatment,[32] which are targeted for T lymphocytes. We further demonstrated that the genus Veillonella was dominant in both high-PD-L1 and immunotherapy responder groups. This finding may contribute to the development of treatment strategies for increasing the effectiveness of immunotherapy in the future.

In this study, Haemophilus, which belongs to the phylum Proteobacteria, showed the largest LDA score of 5.1 in the non-responder group. It is known that most Haemophilus strains are opportunistic pathogens that coexist with the host without causing diseases and only cause diseases during viral infections or decreased immunity. Furthermore, a study showed that Haemophilus was more abundant in patients with lung cancer than in healthy individuals.[33] Our result showed that Haemophilus was abundant in the non-responder group; therefore, it can be inferred that members of this genus lower the effectiveness of anticancer drugs. Thus, Haemophilus may be considered as a target for disease-modulating drugs in lung cancer treatment.

The lung microbiome affects lung immunity and metabolism; several studies have shown that these microbial niches are associated with the pathogenesis of COPD, asthma, cystic fibrosis, and lung cancer.[34–37] Similarly, our study found that the microbiome was related to lung cancer treatment and showed the possibility of devising a method to increase the therapeutic effect using these microbiomes.

This study has a few limitations. First, the daily diet and antibiotic use in the patients, which could have affected the microbial composition, were not investigated in this study. However, bronchoscopy for obtaining the BAL fluid was performed at the time of first diagnosis; therefore, the effect of antibiotics was considered to be minimal. Second, the microbiome differed from one group to another; however, its role in cancer development is unclear. Third, we could not collect data from healthy controls and follow-up BALF to compare microbial differences after cancer treatment.

Despite these limitations, this study was conducted prospectively using 16S rRNA sequencing analysis, which is more sensitive and more informative than the conventional methods. More accurate and elucidating results can be obtained in large-scale studies.

The abundances of Neisseria and Veillonella differed significantly in relation to PD-L1 expression levels and immunotherapy responses. Haemophilus was dominant in the immunotherapy non-responder group; however, the next-generation sequencing analysis did not show significant differences between the alpha and beta diversities in the lung microbiomes of patients in the immunotherapy responder group. Further larger cohort studies are needed to investigate the role of lung microbiome in lung cancer.

Programmed death-ligand 1 (PD-L1)

Non-small cell lung cancer (NSCLC)

Linear discriminant analysis (LDA)

Interquartile ranges (IQR)

Progressive disease (PD)

Stable disease (SD)

Partial response (PR)

Chronic obstructive pulmonary disease (COPD)

Programmed death-protein 1 (PD-1)

Bronchoalveolar lavage (BAL)

LDA effect size (LEFse)

Ethics approval and consent to participate

The research protocol was approved by the Institutional Review Board of Severance Hospital, South Korea (IRB No. 4-0018-0313), and Seoul National University Bundang Hospital, South Korea (IRB No. B-1610/365-302). The study design was approved by the appropriate ethics review boards, and informed patient consent was obtained.

Consent for publication:

Availability of data and materials:

Competing interests:

There is no conflict of interests to declare.

Funding: This work was supported by the National Research Foundation of Korea [Grant No. 2018R1C1B5043991] and the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital [Grant No. 14-2016-011].

Author Contributions: Hye Jin Jang: software, validation, formal analysis, resources, data curation, writing—original draft preparation, visualization; Ji Yeon Choi: software, validation, resources; Kangjoon Kim: software, validation, data curation; Seung Hyun Yong: methodology, software, validation, data curation; Yeon Wook Kim: software, validation, formal analysis, data curation; Song Yee Kim: visualization, software, resources; Eun Young Kim: resources, visualization, software; Ji Ye Jung: formal analysis, resources, visualization; Young Ae Kang: visualization, software, resources; Moo Suk Park: software, investigation, resources; Young Sam Kim: validation, investigation, data curation, writing—review and editing; Young-Jae Cho: Conceptualization, writing—review and editing, visualization, supervision, project administration, funding acquisition; Sang Hoon Lee: Conceptualization, methodology, validation, formal analysis, data curation, writing—review and editing, supervision, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: Not applicable

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health 2019, 85.
Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.
Dickson RP, Huffnagle GB. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog. 2015;11:e1004923.
Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med. 2013;7:245–57.
Cameron SJS, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, Mur LAJ. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One. 2017;12:e0177062.
Tsay J-CJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Li Y, Yie T-A, Lhakhang T, Olsen E. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018;198:1188–98.
Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J, Patumcharoenpol P. PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin. Frontiers in microbiology. 2018;9:1757.
Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, Tal-Singer R, Johnston SL, Ramsheh MY, Barer MR, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47:1082.
Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018;6:92.
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350:1084–9.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84.
Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, Gálvez EM. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. Trends in Cancer. 2020;6:86–97.
Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, Nicod LP, Lloyd CM, Marsland BJ. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med. 2014;20:642–7.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45:228–47.
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell. 2016;165:276–87.
Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–9.
Goto T. Airway Microbiota as a Modulator of Lung Cancer. Int J Mol Sci 2020, 21.
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, Jiang W, Cai S, Zhao P, Song R, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J immunother Cancer. 2019;7:193–3.
Thorsen J, Rasmussen MA, Waage J, Mortensen M, Brejnrod A, Bønnelykke K, Chawes BL, Brix S, Sørensen SJ, Stokholm J, Bisgaard H. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. Nat Commun. 2019;10:5001.
Espuela-Ortiz A, Lorenzo-Diaz F, Baez-Ortega A, Eng C, Hernandez-Pacheco N, Oh SS, Lenoir M, Burchard EG, Flores C, Pino-Yanes M. Bacterial salivary microbiome associates with asthma among african american children and young adults. Pediatr Pulmonol. 2019;54:1948–56.
Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, Moffatt MF, Kim DS, Maher TM. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017;18:29.
Yan X, Yang M, Liu J, Gao R, Hu J, Li J, Zhang L, Shi Y, Guo H, Cheng J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. American Journal of Cancer Research. 2015;5:3111–22.
Rybojad P, Los R, Sawicki M, Tabarkiewicz J, Malm A. Anaerobic bacteria colonizing the lower airways in lung cancer patients. Folia Histochem Cytobiol. 2011;49:263–6.
Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509–21.
Ginefra P, Lorusso G, Vannini N. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. Int J Mol Sci 2020, 21.
Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, Nyman J, Marjanovic ND, Kowalczyk MS, Wang C, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558:454–9.
Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, et al. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunol Res. 2020;8:1251–61.
Druzhinin VG, Matskova LV, Demenkov PS, Baranova ED, Volobaev VP, Minina VI, Apalko SV, Churina MA, Romanyuk SA, Shcherbak SG, et al. Taxonomic diversity of sputum microbiome in lung cancer patients and its relationship with chromosomal aberrations in blood lymphocytes. Sci Rep. 2020;10:9681.
Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384:691–702.
Huang D, Su X, Yuan M, Zhang S, He J, Deng Q, Qiu W, Dong H, Cai S. The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am J Cancer Res. 2019;9:2047–63.
Segal LN, Clemente JC, Tsay JC, Koralov SB, Keller BC, Wu BG, Li Y, Shen N, Ghedin E, Morris A, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol. 2016;1:16031.
Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, Cooper J, Sin DD, Mohn WW, Hogg JC. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1073–80.

Relationship of The Lung Microbiome With PD-L1 Expression And Immunotherapy Response in Lung Cancer

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Patient Recruitment and Sample Collection

Definition of Chemotherapy Response

Statistical Analysis

Ethics Approval and Patient Consent

Results

Characteristics of the Subjects

Characterization of the Lung Microbiome Based on PD-L1 Expression Levels

Taxonomy Composition in Patients with Lung Cancer in the Responder and Non-responder Groups

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1